4-bromo-5-methoxy-2-nitrophenol | 633357-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-5-methoxy-2-nitrophenol
• 英文别名: 4-Brom-5-methoxy-2-nitro-phenol；6-Brom-4-nitro-3-hydroxy-1-methoxy-benzol；Methyl-(6-brom-4-nitro-3-hydroxy-phenyl)-aether
• CAS: 633357-97-8
• 化学式: C₇H₆BrNO₄
• 分子量: 248.033
• InChiKey: NYOZWCXZNLOVBB-UHFFFAOYSA-N

物化性质

• 熔点：
  114 °C
• 沸点：
  328.5±37.0 °C(Predicted)
• 密度：
  1.773±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-bromo-5-methoxy-2-nitrophenol 在 alkaline aqueous NaOBr 作用下， 生成 2,4-dibromo-3-methoxy-6-nitro-phenol
  参考文献：
  名称：

  214.间苯二酚单苯甲酸酯的溴化和4：6-二溴间苯三酚3-苯甲酸酯的硝化。组迁移的示例

  摘要：

  DOI：

  10.1039/jr9350000946
• 作为产物：
  描述：

  3-甲氧基苯酚 在 氯仿 、 硫酸 、 溴 、 溶剂黄146 作用下， 生成 4-bromo-5-methoxy-2-nitrophenol
  参考文献：
  名称：

  214.间苯二酚单苯甲酸酯的溴化和4：6-二溴间苯三酚3-苯甲酸酯的硝化。组迁移的示例

  摘要：

  DOI：

  10.1039/jr9350000946

文献信息

• [EN] 7-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES<br/>[FR] COMPOSÉS DE 7-AZAINDOLE POUR L'INHIBITION DE TYROSINE KINASES BCR-ABL
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022076973A1

  公开（公告）日：2022-04-14

  The present disclosure relates to compounds and compositions for inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as chronic myeloid leukemia (CML).

  本公开涉及抑制Bcr-Abl酪氨酸激酶的化合物和组合物，制备该化合物和组合物的方法，以及它们在治疗各种癌症，如慢性髓细胞白血病（CML）中的使用。
• Kaneniwa, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 785
  作者：Kaneniwa

  DOI：——

  日期：——
• Long-Term Therapy using GHB (Sodium Gamma Hydroxybutyrate) for Treatment-Resistant Chronic Alcoholics
  作者：Icro Marremmani、Francesco Lamanna、Alessandro Tagliamonte

  DOI：10.1080/02791072.2001.10400478

  日期：2001.6

  Thirty-five alcohol-dependent patients according to DSM-IV criteria who also met criteria for treatment resistance were treated with doses of gamma hydroxybutyrate (GHB) ranging between 25 and 100 mg/kg/die in an open one-year study. The results show that no patients discontinued the program during the first month of treatment. Sixty percent of these patients successfully completed the protocol; 11.4% showed complete abstinence (full responder patients); 14.3% strongly reduced their alcohol intake (partial responder patients) and 34.3% of the patients were still under treatment after one year. Forty percent of the patients were nonresponders. The retention rate under treatment of the studied sample was statistically higher than that found during the last treatment of the same subjects. No significant differences were found between full responder and partial responder patients regarding changes in clinical features, alcohol intake or social adjustment. Patients still in treatment after one year significantly differed from nonresponder patients on all the variables investigated. A six-times/daily fractionated administration of the GHB dose was the only significant predictor of the retention rate.